📊 SCNX Key Takeaways
Is Scienture Holdings, Inc. (SCNX) a Good Investment?
Scienture Holdings is a pre-commercial pharmaceutical company with severe operational burn relative to negligible revenue ($56.3K), generating $3.4M net losses on minimal sales despite exceptional 95.6% gross margins. With negative operating cash flow of $2.9M annually and only $3.5M in cash reserves, the company has approximately 12-14 months of runway before potential insolvency without significant external funding or dramatic revenue acceleration. While high gross margins suggest underlying product validity, the company lacks demonstrated commercialization capability and faces extreme execution risk.
Scienture Holdings, Inc. Key Strengths (SCNX)
- Exceptional gross margin of 95.6% indicates strong product pricing power and potentially viable IP/formulations when commercialized
- Conservative capital structure with minimal debt (Debt/Equity 0.03x) and low interest coverage risk
- Substantial asset base of $80.7M and stockholders equity of $66.8M provide liquidity buffer for near-term operations
SCNX Stock Risks: Scienture Holdings, Inc. Investment Risks
- Severe cash burn of $2.9M operating cash flow against trivial $56.3K revenue creates existential solvency risk within 12-14 months without funding
- Operating margin of -6230.8% and net margin of -6040.4% indicate company is not operationally viable at current revenue levels
- Pre-commercial or extremely early-stage company with minimal market traction; revenue of $56.3K suggests little to no commercialization success to date
Key Metrics to Watch
- Quarterly revenue trajectory and absolute revenue growth toward breakeven thresholds
- Operating cash burn rate and cash reserves depletion timeline
- Gross margin sustainability as revenue scales and production/commercialization ramps
Scienture Holdings, Inc. (SCNX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Scienture Holdings, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
SCNX Profit Margin, ROE & Profitability Analysis
SCNX vs Healthcare Sector: How Scienture Holdings, Inc. Compares
How Scienture Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Scienture Holdings, Inc. Stock Overvalued? SCNX Valuation Analysis 2026
Based on fundamental analysis, Scienture Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Scienture Holdings, Inc. Balance Sheet: SCNX Debt, Cash & Liquidity
SCNX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Scienture Holdings, Inc.'s revenue has declined by 97% over the 5-year period, indicating business contraction. The most recent EPS of $2.48 reflects profitable operations.
SCNX Revenue Growth, EPS Growth & YoY Performance
SCNX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $10.3K | -$3.1M | $-0.08 |
| Q3 2025 | $64.9K | -$1.8M | $-0.19 |
| Q2 2025 | $10.3K | -$1.8M | $-0.48 |
| Q1 2025 | $10.3K | -$3.1M | $-0.33 |
| Q3 2024 | $64.9K | -$678.0K | $-1.34 |
| Q2 2024 | $18.7K | -$678.0K | $-1.30 |
| Q1 2024 | $493.3K | -$678.0K | $-1.01 |
| Q3 2023 | $2.1M | -$503.0K | $-0.91 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Scienture Holdings, Inc. Dividends, Buybacks & Capital Allocation
SCNX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Scienture Holdings, Inc. (CIK: 0001382574)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SCNX
What is the AI rating for SCNX?
Scienture Holdings, Inc. (SCNX) has an AI grade of D with 87% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SCNX's key strengths?
Claude: Exceptional gross margin of 95.6% indicates strong product pricing power and potentially viable IP/formulations when commercialized. Conservative capital structure with minimal debt (Debt/Equity 0.03x) and low interest coverage risk.
What are the risks of investing in SCNX?
Claude: Severe cash burn of $2.9M operating cash flow against trivial $56.3K revenue creates existential solvency risk within 12-14 months without funding. Operating margin of -6230.8% and net margin of -6040.4% indicate company is not operationally viable at current revenue levels.
What is SCNX's revenue and growth?
Scienture Holdings, Inc. reported revenue of $56.3K.
Does SCNX pay dividends?
Scienture Holdings, Inc. pays dividends, with $14.9M distributed to shareholders in the trailing twelve months.
Where can I find SCNX SEC filings?
Official SEC filings for Scienture Holdings, Inc. (CIK: 0001382574) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SCNX's EPS?
Scienture Holdings, Inc. has a diluted EPS of $-0.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SCNX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Scienture Holdings, Inc. has a D grade with 87% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SCNX stock overvalued or undervalued?
Valuation metrics for SCNX: ROE of -5.1% (sector avg: 15%), net margin of -6,040.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SCNX's AI grade for 2026?
Our dual AI analysis gives Scienture Holdings, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SCNX's free cash flow?
Scienture Holdings, Inc.'s operating cash flow is $-2.9M, with capital expenditures of $12.0K. FCF margin is -5,204.2%.
How does SCNX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -6,040.4% (avg: 12%), ROE -5.1% (avg: 15%), current ratio 1.70 (avg: 2).